Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 2/20 | 0.57 |
| ▸ | GRK5 | P34947 | 2/20 | 0.57 |
| ▸ | TYRO3 | Q06418 | 2/20 | 0.57 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.57 |
| ▸ | CA2 | P00918 | 11/20 | 0.46 |
| ▸ | CA12 | O43570 | 11/20 | 0.46 |
| ▸ | CA9 | Q16790 | 11/20 | 0.46 |
| ▸ | CA1 | P00915 | 9/20 | 0.46 |
| ▸ | CA4 | P22748 | 7/20 | 0.46 |
| ▸ | CA7 | P43166 | 7/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | BCHE | P06276 | 1/20 | 0.46 |
| ▸ | CA6 | P23280 | 1/20 | 0.46 |
| ▸ | CA5A | P35218 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.46 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.46 |
| ▸ | ELANE | P08246 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7281544 | 0.84 | RET (0.51) | RETGRK5TYRO3DYRK1BCA2 | |
| SCHEMBL9407224 | 0.84 | RET (0.51) | RETGRK5TYRO3DYRK1BCA2 | |
| SCHEMBL7287920 | 0.83 | RET (0.50) | RETGRK5TYRO3DYRK1BCA2 | |
| SCHEMBL7281756 | 0.82 | RET (0.53) | RETGRK5TYRO3DYRK1BCA2 | |
| SCHEMBL8087845 | 0.80 | RET (0.58) | RETGRK5TYRO3DYRK1BCA2 | |
| SCHEMBL7023285 | 0.77 | RET (0.62) | RETGRK5TYRO3DYRK1BCA2 | |
| SCHEMBL20646900 | 0.76 | RET (0.53) | RETGRK5TYRO3DYRK1BCA2 | |
| SCHEMBL9737868 | 0.75 | CA12 (0.41) | RETGRK5TYRO3DYRK1BCA2 | |
| SCHEMBL7280743 | 0.74 | RET (0.59) | RETGRK5TYRO3DYRK1BCA2 | |
| SCHEMBL7012037 | 0.73 | ELANE (0.41) | RETGRK5TYRO3DYRK1BCA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018115-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | LOXO ONCOLOGY, INC. | 2024-01-18 | — | — | US | disclosed |
| EP-0547708-B1 | Saccharin derivative proteolytic enzyme inhibitors | SANOFI SYNTHELABO (FR) | 2003-02-26 | — | — | EP | disclosed |
| US-5874432-A | Saccharin derivatives useful as proteolytic enzyme inhibitors and compositions and method of use thereof | SANOFI (FR) | 1999-02-23 | — | — | US | disclosed |
| US-5650422-A | TREATMENT OF EMPHYSEMA, ARTHRITIS OR PANCREATITIS | SANOFI (FR) | 1997-07-22 | — | — | US | disclosed |
| US-5596012-A | Saccharin derivatives useful as proteolytic enzyme inhibitors and compositions and method of use thereof | STERLING WINTHROP INC. (US) | 1997-01-21 | — | — | US | disclosed |
| US-5466701-A | Degenerative diseases | STERLING WINTHROP INC. (US) | 1995-11-14 | — | — | US | disclosed |
| US-5378720-A | Treatment of rheumatoid arthritis, emphysema, pancreatitis | STERLING WINTHROP INC. (US) | 1995-01-03 | — | — | US | disclosed |
| US-5371074-A | Use of saccharin derivatives as proteolytic enzyme inhibitors | STERLING WINTHROP INC. (US) | 1994-12-06 | — | — | US | disclosed |
| EP-0626378-A1 | Saccharin derivative proteolytic enzyme inhibitors | STERLING WINTHROP INC. (US) | 1994-11-30 | — | — | EP | disclosed |
| US-5236917-A | Respiratory system disorders, antiarthritic agents | STERLING WINTHROP INC. (US) | 1993-08-17 | — | — | US | disclosed |
| EP-0547708-A1 | Saccharin derivative proteolytic enzyme inhibitors | STERLING WINTHROP INC. (US) | 1993-06-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018115-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | PIK3CA, PIK3R4, PIK3R5 | RET 193/4885GRK5 79/4885TYRO3 554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.